Glutamic acid not beneficial for the prevention of vincristine neurotoxicity in children with cancer

Pediatric Blood and Cancer

Volumn 62, Issue 6, 2015, Pages 1004-1010

  Bradfield, Scott M ^a   Sandler, Eric ^a   Geller, Thomas ^b   Tamura, Roy N ^c   Krischer, Jeffrey P ^c  

^a NEMOURS CHILDREN S CLINIC   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Chemotherapy neurotoxicities; Lymphoblastic leukemia neurology; Pediatric oncology; Quality of life; Support care

Indexed keywords

GLUTAMIC ACID; NEUROPROTECTIVE AGENT; PLACEBO; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CHILD; CHILDHOOD CANCER; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERBILIRUBINEMIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEPHROBLASTOMA; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOSARCOMA; SCHOOL CHILD; SEIZURE; SENSORY NEUROPATHY; STATISTICAL SIGNIFICANCE; STOMATITIS; TREATMENT DURATION; VOMITING; ADOLESCENT; NEOPLASMS; NEUROTOXICITY SYNDROMES; PRESCHOOL CHILD;

ADOLESCENT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; GLUTAMIC ACID; HUMANS; MALE; NEOPLASMS; NEUROTOXICITY SYNDROMES; VINCRISTINE;

EID: 84927794404     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25384     Document Type: Article

References (21)

1. Duflos A, Kruczynski A, Barret JM. Novel aspects of natural and modified vinca alkaloids. Curr Med Chem Anticancer Agents 2002; 2:55-70.
2. Rowinsky EK, Donehower RC. The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol Ther 1991; 52:35-84.
3. Sandler SG, Tobin W, Henderson ES. Vincristine-induced neuropathy. A clinical study of fifty leukemic patients. Neurology 1969; 19:367-374.
4. Rosenthal S, Kaufman S. Vincristine neurotoxicity. Ann Intern Med 1974; 80:733-737.
5. Schlaepfer WW. Vincristine-induced axonal alterations in rat peripheral nerve. J Neuropathol Exp Neurol 1971; 30:488-505.
6. Tanner KD, Levine JD, Topp KS. Microtubule disorientation and axonal swelling in unmyelinated sensory axons during vincristine-induced painful neuropathy in rat. J Comp Neurol 1998; 395:481-492.
7. Topp KS, Tanner KD, Levine JD. Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat. J Comp Neurol 2000; 424:563-576.
8. Bleyer WA, Frisby SA, Oliverio VT. Uptake and binding of vincristine by murine leukemia cells. Biochem Pharmacol 1975; 24:633-639.
9. Alexander JE, Hunt DF, Lee MK, Shabanowitz J, Michel H, Berlin SC, MacDonald TL, Sundberg RJ, Rebhun LI, Frankfurter A. Characterization of posttranslational modifications in neuron-specific class, III, beta-tubulin by mass spectrometry. Proc Natl Acad Sci USA 1991; 88:4685-4689.
10. Pirollet F, Margolis RL, Job D. Ca(2+)-calmodulin regulated effectors of microtubule stability in neuronal tissues. Biochem Biophys Acta 1992; 1160:113-119.
11. Esmaeli-Azad B, McCarty JH, Feinstein SC. Sense and antisense transfection analysis of tau function: tau influences net microtubule assembly, neurite outgrowth and neuritic stability. J Cell Sci 1994; 107:869-879.
12. Jackson DV, Wells HB, Atkins JN, Zekan PJ, White DR, Richards F 2nd, Cruz JM, Muss HB. Amelioration of vincristine neurotoxicity by glutamic acid. Am J Med 1988; 84:1016-1022.
13. Weiss HD, Walker MD, Wiernik PH. Neurotoxicity of commonly used antineoplastic agents (first of two parts). N Engl J Med 1974; 291:75-81.
14. Pal PK. Clinical and electrophysiological studies in vincristine induced neuropathy. Electromyogr Clin Neurophysiol 1999; 39:323-330.
15. Jackson DV, Pope EK, Case LD, Wells HB, White DR, Cooper MR, Caldwell RD, Black WR, Muss HB, Cruz JM, Spurr CL, Capizzi L. Improved tolerance of vincristine by glutamic acid. A preliminary report. J Neurooncol 1984; 2:219-222.
16. Boyle FM, Wheeler HR, Shenfield GM. Glutamate ameliorates experimental vincristine neuropathy. J Pharmacol Exp Ther 1996; 279:410-415.
17. Mokhtar GM, Shaaban SY, Elbarbary NS, Fayed WA. A trial to assess the efficacy of glutamic acid in prevention of vincristine-induced neurotoxicity in pediatric malignancies: A pilot study. J Pediatr Hematol Oncol 2010; 32:594-600.
18. Jackson DV, Rosenbaum DL, Carlisle LJ, Long TR, Wells HB, Spurr CL. Glutamic acid modification of vincristine toxicity. Cancer Biochem Biophys 1984; 7:245-252.
19. Smith EML, Li L, Hutchinson RJ, Ho R, Burnette WB, Wells E, Bridges C, Renbarger J. Measuring vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. Cancer Nurs 2013; 36:E49-E60.
20. Egbelakin A, Ferguson MJ, MacGill EA, Lehmann AS, Topletz AR, Quinney SK, Li L, McCammack KC, Hall SD, Renbarger JL. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2011; 56:361-367.
21. Chauvenet AR, Shashi V, Selsky C, Morgan E, Kurtzberg J, Bell B. Vincristine-induced neuropathy as the initial presentation of Charcot-Marie-Tooth disease in acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Pediatr Hematol Oncol 2003; 25:316-320.